Home - Products - Others - Other Targets - Quercetin-3-gentiobioside

Quercetin-3-gentiobioside

CAS No. 7431-83-6

Quercetin-3-gentiobioside( —— )

Catalog No. M31440 CAS No. 7431-83-6

Quercetin 3-gentiobioside is an inhibitor of AR and AGE formation and can be extracted from A. iwayomogi.Quercetin 3-gentiobioside inhibits the biological activity of aldose reductase (AR) and the formation of advanced glycosylation end products (AGEs).

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
5MG	248	In Stock
10MG	422	In Stock
50MG	Get Quote	In Stock
100MG	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Quercetin-3-gentiobioside
Note

Research use only, not for human use.
Brief Description

Quercetin 3-gentiobioside is an inhibitor of AR and AGE formation and can be extracted from A. iwayomogi.Quercetin 3-gentiobioside inhibits the biological activity of aldose reductase (AR) and the formation of advanced glycosylation end products (AGEs).
Description

Quercetin 3-gentiobioside is an inhibitor of AR and AGE formation and can be extracted from A. iwayomogi.Quercetin 3-gentiobioside inhibits the biological activity of aldose reductase (AR) and the formation of advanced glycosylation end products (AGEs).
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

——
Research Area

——
Indication

——

Chemical Information

CAS Number

7431-83-6
Formula Weight

626.5
Molecular Formula

C27H30O17
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : 100 mg/mL (159.61 mM)
SMILES

——
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

Fletikumab

Fletikumab (NNC0109-0012) is a monoclonal antibody that inhibits IL-20, primarily used in research on rheumatoid arthritis and psoriasis.
Axillarin

Axillarin has antioxidant activity, it shows xanthine oxidase inhibitory activity ( IC(50) :36.0 uM).
Linzagolix

Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis.

Sign In Join Free